Class of Stock [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Legal Entity [Axis] Cirna Diagnostics LLC [Member] Statistical Measurement [Axis] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Securities Purchase Agreements [Member] Title and Position [Axis] Investors [Member] Sale of Stock [Axis] Private Placement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Warrant [Member] Class of Warrant or Right [Axis] Series A Common Warrant [Member] Series B Common Warrant [Member] Series A Warrant [Member] Series B Warrant [Member] Series A and B Common Warrant [Member] Prefunded Warrant [Member] Minimum [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] 2025 Series A Warrants [Member] Series A Warrants [Member] Series B-1 Warrants [Member] 2025 Series A Warrants [Member] Liability Class [Axis] Derivative Financial Instruments, Liabilities [Member] Directors And Officers Liability Agreement [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Plan Name [Axis] 2013 Equity Incentive Plan [Member] 2023 Omnibus Equity Incentive Plan [Member] Location, Statement of Income, Balance [Axis] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Antidilutive Securities [Axis] Warrants Liability [Member] LoPriore Employment Agreement [Member] Stetz Employment Agreement [Member] Separation Agreement [Member] New Day Diagnostics LLC [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] Assets Current assets: Cash Prepaid expenses Total current assets Total assets Liabilities and Stockholders’ Equity Current liabilities: Accounts payable Accrued expenses Notes payable, current Total current liabilities Derivative financial instruments—warrants Total liabilities Commitments and contingencies (see Note 10) Stockholders’ equity: Convertible preferred stock Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 29,120,317 and 11,620,317 issued and outstanding at June 30, 2026 and December 31, 2025, respectively. Additional paid-in capital Accumulated other comprehensive income. Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Convertible preferred stock, par value Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost and expenses: Research and development General and administrative Asset impairment loss Total operating expenses Loss from operations Other income (expense): Interest income (expense) Change in fair value of derivative financial instruments-warrants Net loss Weighted-average common shares outstanding: Basic Diluted Net loss per common share: (see Note 9) Basic Diluted Net loss Other comprehensive income (loss): Foreign currency translation Total other comprehensive income (loss) Comprehensive loss Balance Balance, shares Issuance of common stock, net Issuance of common stock, shares Stock-based compensation expense Issuance of restricted stock units Issuance of restricted stock units, shares Issuance of common stock and pre-funded warrants, net Issuance of common stock and pre-funded warrants, net, shares Issuance of common stock in connection with stock split Issuance of common stock in connection with stock split, shares Conversion of 2025 Series B warrants into common stock Conversion of 2025 Series B warrants into common stock, shares Issuance of common stock in connection with license agreement Issuance of common stock in connection with license agreement, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Asset impairment loss Change in fair value of derivative financial instruments—warrants Changes in operating assets and liabilities: Accounts payable and accrued expenses Prepaid expenses and other assets Net cash used in operating activities Cash flows from investing activities: Investment in license agreement Net cash used in investing activities Cash flows from financing activities: Proceeds from the issuance of common stock and warrants, net Equity issuance costs Payments on notes payable Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Supplementary disclosure of non-cash financing activities: Issuance of Note Payable for payment of prepaid expense Cashless Exercise of 2025 Series B Warrants Issuance of common stock in connection with license agreement Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Equity Awards Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Overview Accounting Policies [Abstract] Basis of Presentation Summary of Significant Accounting Policies Equity [Abstract] Stockholders’ Equity Debt Disclosure [Abstract] Notes Payable Fair Value Disclosures [Abstract] Fair Value Measurements Payables and Accruals [Abstract] Accrued Liabilities Share-Based Payment Arrangement [Abstract] Accounting for Share-Based Payments Earnings Per Share [Abstract] Loss per Share Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Use of Estimates Recent Accounting Pronouncements Schedule of Assumptions Used to Calculate Fair Value of Liability Schedule of Warrants Outstanding and Fair Value for Warrants Schedule of Derivative Liabilities at Fair Value Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis Schedule of Accrued Liabilities Schedule of Stock Based Compensation Expense Schedule of Stock Option Activity Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Outstanding Securities Excluded from Computation of Basic and Diluted Weighted Shares Outstanding Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments to acquire intangible assets Patent expenses Sales milestone payments Payments to acquire in process research and development Accumulated deficit Working capital Cash used in operating activities Aggregate offering of shares Common stock par value Offering price per share Gross proceeds Warrants price per share Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Warrants measurement input Expected warrant term (years) Stock, Class of Stock [Table] Class of Stock [Line Items] Exercise Price Warrants Outstanding Fair Value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Number of Warrants Outstanding, Beginning balance Derivative Instrument Liability, Beginning balance Number of Warrants Outstanding, Change in fair value of warrants Derivative Instrument Liability, Change in fair value of warrants Number of Warrants Outstanding, Ending balance Derivative Instrument Liability, Ending balance Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary, Sale of Stock [Line Items] Number of share common stock sold Conversion of shares Preferred stock, par value per share Preferred stock, convertible conversion price Exercise price Pre funded warrant permanent equity Common stock and/or pre-funded warrants Derivative Liability Warrants exercised Fair value of Series A warrant liability Unexercised Series A warrants Incurred equity issuance costs Warrant liability Fair value adjustment of warrants Gross proceeds Notes payable Exercise price Number of warrants Exercisable common shares Series A warrants Fair value of warrants Down payment Annual percentage rate Periodic payment description Monthly payments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Derivative liabilities related to warrants Payroll related Accrued taxes Other Total accrued expenses Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of options outstanding, beginning balance Weighted average exercise price per share, beginning balance Intrinsic value, beginning balance Weighted average remaining contractual term Number of options, forfeited Weighted average exercise price per share, forfeited Intrinsic value, forfeited Number of options outstanding, ending balance Weighted average exercise price per share, ending balance Intrinsic value, ending balance Number of options outstanding, vested awards and those expected to vest Weighted average exercise price per share, vested awards and those expected to vest Intrinsic value, vested awards and those expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Number of options, vested and exercisable Weighted average exercise price per share, vested and exercisable Intrinsic value, vested and exercisable Weighted Average Remaining Contractual Term Vested period Expiration period Share based payments granted Awards available for grant Unrecognized compensation cost related to non-vested stock Numerator: Denominator: Weighted average common shares outstanding, Basic Weighted average common shares outstanding, Diluted Net loss per share of common stock, Basic Net loss per share of common stock, Diluted Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total Employees benefit description Base salary Sign on bonus, received Services costs Bonuses Subsequent Event [Table] Subsequent Event [Line Items] Common stock shares return Shares initially issued Offering price per share Change in fair value of contingent consideration and derivative financial instruments. Warrant inducement expense. Stock issued during period value issuance of common stock and prefunded warrants. Stock issued during period value of connection with stock split. Issuance of common stock in connection with license agreement. Stock issued during period shares issuance of common stock and prefunded warrants. Stock issued during period shares of connection with stock split. Stock issued during period shares of connection with license agreement. Issuance of note payable for payment of prepaid expense. Cashless exercise of warrants. Cirna Diagnostics LLC [Member] Patent expenses amount. Working capital. Securities Purchase Agreements [Member] Investors [Member] Series A Warrants [Member] Series B-1 Warrants [Member] 2025 Series A Warrants [Member] Series A Common Warrant [Member] Series B Common Warrant [Member] Pre funded of warrant description. Series A Warrant [Member] Series B Warrant [Member] Stock issued during period shares warrant exercises. Fair value of warrants exercised and warrant liability. Remaining number of unexercised warrants. Adjustments to additional paid in capital. Fair value adjustment of warrants liability. Series A and B Common Warrant [Member] Prefunded Warrant [Member] 2025 Series A Warrants [Member] Number of warrants outstanding shares increase decrease. Directors And Officers Liability Agreement [Member] Down payment. Accrued license fees. 2013 Equity Incentive Plan [Member] 2023 Omnibus Equity Incentive Plan [Member] Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Intrinsic Value. Payments for services costs. Separation Agreement [Member] Common stock shares return. New Day Diagnostics LLC [Member] Warrants Liability [Member] 2025 Series A Warrant [Member] Change in fair value of derivative financial instruments warrants. Issuance of common stock in connection with license agreement. Employees benefit description LoPriore Employment Agreement [Member] Stetz Employment Agreement [Member] Sign on bonus received 2025 Series A Warrants [Member] [Default Label] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Asset, Impairment Loss Increase (Decrease) in Prepaid Expense and Other Assets Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Payments to Acquire Investments Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Repayments of Notes Payable Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation IssuanceOfCommonStockInConnectionWithLicenseAgreement Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Proceeds from Warrant Exercises Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Shares Issued, Price Per Share